In Brief: Endocare/Aloka Ultrasound
This article was originally published in The Gray Sheet
Executive Summary
Endocare/Aloka Ultrasound: Firms enter strategic alliance for the U.S. marketing of Endocare's Cryocare cryotherapy system for treating prostate cancer. Under the agreement, Aloka will help train users of the Cryocare system in the proper use of ultrasound with cryotherapy. In exchange, Aloka gains rights to sell its ultrasound systems to Endocare's customer base. "Having the strength of a premier ultrasound company like Aloka helping us market cryotherapy will result in a more complete presentation to our customers," Endocare says. The Cryocare system, which uses an argon gas-based cryogen, was cleared by FDA in mid-1995 and formally introduced by Endocare at the recent American Urological Association annual meeting in Orlando...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.